Eli Lilly

News

Lilly shrugs off concerns about the effect of US drug pricing policies on its diabetes and weight loss drugs as revenues leap 39% to $24.4bn.

News

Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.

News

A US judge has blocked Novo's request for an injunction on Eli Lilly's advertising for weight-loss and diabetes drugs Mounjaro and Zepbound.

News

Trials of Lilly's Omvoh, Gilead's emvistegrast, Takeda's Entyvio, AbbVie's ABBV-466, and Sanofi/Teva's duvakitug are highlights of UEGW.

News

Eli Lilly's oral GLP-1 Foundayo has been recommended for weight reduction and type 2 diabetes in the EU, plus other CHMP decisions.

News

A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.